Latest post

Positive phase 1 data indicate THR-687 could be an effective therapy for patients with DME

Oxurion kick-started 2020 with positive topline data from phase 1 clinical trial evaluating THR-687 for treatment of DME.

back of the eye diseases, science community,

Professor Alan Stitt: Researching the AMD pathway

An interview with Alan Stitt about research in the AMD field.

back of the eye diseases, science community,

Research opportunities for treating age-related macular degeneration

Age-related macular degeneration (or AMD) is the leading cause of blindness. At Oxurion, we’re discovering new ways to treat both forms.